Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
Boston Medical Center is the winner of the AHA’s 2024 Foster G. McGaw Prize, which recognizes the efforts of hospitals and health systems to improve the health…
Headline
In the latest "Safety Speaks" conversation, Christi Barney, R.N., vice president of quality and patient safety at Emerson Health, discusses the health system’s…
Headline
In a new blog, Chris DeRienzo, M.D., AHA’s senior vice president and chief physician executive, highlights three ways this year's AHA Leadership Summit…
Blog
From plenaries to interactive sessions to podcasts, the AHA’s Patient Safety Initiative had a huge presence at last month’s AHA Leadership Summit. Over three…
Chairperson's File
Today’s health care workforce uses an amazing array of creative approaches, strategies and technology tools to ensure every patient receives quality care.At…
Headline
In a new "Safety Speaks" conversation, Jamie Orlikoff, president of Orlikoff & Associates, Inc. and AHA national adviser on governance and leadership,…